Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does AVAPRITINIB Cause Chronic obstructive pulmonary disease? 5 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Chronic obstructive pulmonary disease have been filed in association with AVAPRITINIB (Ayvakit). This represents 0.1% of all adverse event reports for AVAPRITINIB.

5
Reports of Chronic obstructive pulmonary disease with AVAPRITINIB
0.1%
of all AVAPRITINIB reports
0
Deaths
2
Hospitalizations

How Dangerous Is Chronic obstructive pulmonary disease From AVAPRITINIB?

Of the 5 reports, 2 (40.0%) required hospitalization.

Is Chronic obstructive pulmonary disease Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for AVAPRITINIB. However, 5 reports have been filed with the FAERS database.

What Other Side Effects Does AVAPRITINIB Cause?

Fatigue (1,527) Off label use (1,138) Nausea (1,033) Diarrhoea (886) Swelling face (481) Memory impairment (467) Dizziness (458) Vomiting (456) Headache (454) Asthenia (433)

What Other Drugs Cause Chronic obstructive pulmonary disease?

ALBUTEROL (2,916) TIOTROPIUM (2,895) BUDESONIDE\FORMOTEROL (2,279) FLUTICASONE\SALMETEROL (1,904) ADALIMUMAB (1,712) PREDNISONE (1,237) FLUTICASONE FUROATE\UMECLIDINIUM\VILANTEROL TRIFENATATE (1,145) MEPOLIZUMAB (1,107) FLUTICASONE FUROATE\VILANTEROL TRIFENATATE (967) DUPILUMAB (907)

Which AVAPRITINIB Alternatives Have Lower Chronic obstructive pulmonary disease Risk?

AVAPRITINIB vs AVASTIN AVAPRITINIB vs AVATROMBOPAG AVAPRITINIB vs AVELOX AVAPRITINIB vs AVELUMAB AVAPRITINIB vs AVIBACTAM

Related Pages

AVAPRITINIB Full Profile All Chronic obstructive pulmonary disease Reports All Drugs Causing Chronic obstructive pulmonary disease AVAPRITINIB Demographics